Effect of hirudin versus heparin on hemocompatibility of blood contacting biomaterials: An in vitro study

International Journal of Artificial Organs

Volumn 28, Issue 12, 2005, Pages 1272-1277

  Kopp, Ruedger ^a   Bensberg, R ^a   Kashefi, A ^a   Mottaghy, K ^a   Rossaint, R ^a   Kuhlen, R ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Blood coagulation; Blood platelets; Complement; Hemocompatibility; Heparin; Hirudin; In vitro

Indexed keywords

CHEMICAL ACTIVATION; COAGULATION; PLATELETS;

ANTI-COAGULATION; BLOOD CIRCULATION; BLOOD COAGULATION; BLOOD PLATELETS; COMPLEMENT; HAEMOCOMPATIBILITY; HIRUDIN; HUMAN BLOODS; IN-VITRO; VITRO STUDIES;

POLYSACCHARIDES;

BIOMATERIAL; COMPLEMENT COMPONENT C5A; D DIMER; HEPARIN; HIRUDIN; POLYVINYLCHLORIDE; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE FACTOR 4;

ANALYZER; ANTICOAGULATION; ARTICLE; BIOCOMPATIBILITY; BLOOD CLOTTING; BLOOD FLOW; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; EXTRACORPOREAL CIRCULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NORMAL HUMAN; TEMPERATURE; THROMBOCYTE; THROMBOCYTE ACTIVATION;

EID: 31644431954     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880502801211     Document Type: Article

References (16)

1. Edmunds LH. Why cardiopulmonary bypass makes patients sick: Strategies to control the blood-synthetic surface interface. Adv Card Surg 1995; 6: 131-67.
2. Sanchez J, Elgue G, Riesenfeld J, Olsson P. Studies of absorption, activation and inhibition of factor XII on immobilized heparin. Thromb Res 1998; 89: 41-50.
3. Kopp R, Mottaghy K, Kirschfink M. Mechanism of complement activation during extracorporeal blood-biomaterial interaction: Effects of heparin coated and uncoated surfaces. ASAIO J 2002; 48: 598-605.
4. Greinacher A. Heparin-induced thrombocytopenia-pathogenesis and treatment. Thromb Haemost 1999; 82: 148-56.
5. Fischer KG, van de Loo A, Bohler J. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int 1999; 72 (suppl): S46-50.
6. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: Focus on lepirudin. Circulation 2001; 103: 1479-84.
7. Gallistl S, Muntean W. Thrombin-hirudin complex formation, thrombin-antithrombin III complex formation, and thrombin generation after intrinsic activation of plasma. Thromb Haemost 1994; 72: 387-92.
8. Kaiser B, Koza M, Walenga JM, Fareed J. Flow cytometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole blood. Thromb Res 1996; 82: 257-63.
9. Glusa E. Platelet aggregation in recombinant-hirudin-anticoagulated blood. Haemostasis 1991; 21: 116-20.
10. Mollnes TE, Brekke OL, Fung M, et al. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002; 100: 1869-77.
11. Haaland AK, Skjonsberg OH, Gravem K, Ruyter R, Godal HC. Comparison of thrombin-antithrombin complex (TAT) levels and fibrinopeptide A following thrombin incubation of human plasma using hirudin as an inhibitor of TAT formation. Thromb Res 1991; 61: 253-9.
12. Hayes KL, Tracy PB. The platelet high affinity binding site for thrombin mimics hirudin, modulates thrombin-induced platelet activation, and is distinct from the glycoprotein lb-IX-V complex. J Biol Chem 1999; 274: 972-80.
13. Gong J, Larsson R, Ekdahl KN, Mollnes TE, Nilsson U, Nilsson B. Tubing loops as a model for cardiopulmonary bypass circuits: Both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model. J Clin Immunol 1996; 16: 222-9.
14. Spijker HT, Graaff R, Boonstra PW, Busscher HJ, van Oeveren W. On the influence of flow conditions and wettability on blood material interactions. Biomaterials 2003; 24: 4717-27.
15. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood 1996; 88: 1525-41.
16. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.